Synageva BioPharma Inactive 10-K2014 FY Annual report

Filed: 26 Feb 15, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: adrenal, affair, arm, asthenia, atypical, audience, Bazemore, begun, beneficiary, bilirubin, brand, Brazilian, bridging, budgetary, built, calcification, category, cohort, conference, constipation, cryptogenic, CSF, deceased, demanding, deposit, dialogistic, discontinued, East, ectonucleotide, elasticum, encountered, etiology, exempt, Exploratory, ferritin, FH, footnote, frequency, GACI, GCP, gender, GLP, heart, hematological, hemoglobin, hepatosplenomegaly, herewith, Hunter, hypercholesterolemia, hypophosphatemic, IASB, injury, interpreted, inviting, Ishak, jointly, Kanuma, lack, longitudinal, magnitude, Media, medium, methodology, Mexican, Middle, misdiagnosed, Mitsbushi, multicenter, NAFLD, NASH, NASPGHAN, neurocognitive, nonalcoholic, nonclinical, notable, oral, oropharyngeal, overcome, overstated, overview, parallel, PDUFA, Peso, pharmacovigilance, potent, power, PPi, primate, pseudoxanthoma, pyrexia, pyrophosphate, rata, real, recoverable, relaxation, reserved, reside, Robert, score, sector, septa, South, specialist, statistical, sudden, syndrome, temperature, thrive, twe, unexplained, unsure, urine, Vice, VIE, visually, vomiting, wrote, Yen

Removed: acquiring, acquiror, advanced, alter, appointed, Asia, attain, Australia, automatically, autosomal, BCPI, Brazil, calculated, Canada, cardiovascular, cellular, CESD, characterized, China, cholesteryl, consistency, contemplated, contrast, converted, deductible, dose, EITF, emerging, encouraging, epigenetic, Escalation, ester, exchanged, exclude, existence, expedited, experiencing, Flexibility, forma, fraction, fractional, genome, globally, hearing, highlighted, identification, immortalized, importance, inclusion, inconsistency, IRS, Latin, malabsorption, mammalian, maximize, mechanism, mediated, mutation, NIH, occupy, offsetting, opportunity, oviduct, Pacific, par, perspective, placement, proportionally, recessive, reclassified, registry, reliable, relieved, represented, residual, revaluation, revised, Secretary, secretion, selective, spectrum, spending, split, substrate, tailored, tight, tolerated, tranche, turn, type, undelivered, unused, vendor, vested, voting, Wolman

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Synageva BioPharma similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002*

Pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, each of the undersigned, as principal executive officer and principal financial officer of Synageva BioPharma Corp. (the “Company”), does hereby certify that to such officer’s knowledge:

(1) the Company’s Form 10-K for the period ended December 31, 2014 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Company’s Form 10-K for the period ended December 31, 2014 fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Sanj K. Patel

Sanj K. Patel

President and Chief Executive Officer

/s/ Carsten Boess

Carsten Boess

Senior Vice President, Chief Financial Officer

Date: February 26, 2015

*	A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to Synageva BioPharma Corp. and will be retained by Synageva BioPharma Corp. and provided to the Securities and Exchange Commission or its staff upon request.